<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553018</url>
  </required_header>
  <id_info>
    <org_study_id>MD-112014</org_study_id>
    <nct_id>NCT02553018</nct_id>
  </id_info>
  <brief_title>Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe</brief_title>
  <acronym>Self-i</acronym>
  <official_title>A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Pharma SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Pharma SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare, in patients treated with methotrexate&#xD;
      injection for rheumatoid arthritis, the compliance and the health assessment questionnaire&#xD;
      evolution for the administration by auto-injector versus administration by conventional&#xD;
      subcutaneous injection, after 6 months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary criteria: observance and health assessment questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>the health assessment questionnaire is completed by the patient at inclusion visit and at the 6 months visit. Compliance with methotrexate treatment will be assessed by the investigator at each visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Patient's quality of life will be assessed using a validated questionnaire. completed by the patient at inclusion and 6 months visits. Change from baseline in questionnaire score will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acceptability</measure>
    <time_frame>up to 1 year</time_frame>
    <description>The product acceptability will be evaluated by the patient using a specific questionnaire based on several questions related to the patient' opinion, satisfaction and willingness to adopt the product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preference</measure>
    <time_frame>6 months</time_frame>
    <description>Preference will be assessed only for patients receiving auto-injector and pre-filled syringe of methotrexate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic</measure>
    <time_frame>6 months</time_frame>
    <description>Information on the consumed resources for methotrexate administration will be assessed at 6 months. This information will be further incorporated in a budget impact for the French Sickness Fund</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Auto-injector of methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.&#xD;
Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.&#xD;
Frequency: one injection per week Duration: until the end of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-filled syringe of methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.&#xD;
Frequency: one injection per week Duration: until the end of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Auto-injector of methotrexate</arm_group_label>
    <arm_group_label>Pre-filled syringe of methotrexate</arm_group_label>
    <other_name>Auto-injector of methotrexate</other_name>
    <other_name>METOJECT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (18 years or over) of either sex.&#xD;
&#xD;
          -  With established rheumatoid arthritis diagnosis&#xD;
&#xD;
          -  Treated for rheumatoid arthritis by methotrexate (oral or by injection) since at least&#xD;
             3 months regardless of the prior or combined disease modifying treatment, except&#xD;
             biotherapies and justifying injection of methotrexate. For the patient treated by oral&#xD;
             methotrexate, the switch decided by the rheumatologist is made for either safety,&#xD;
             compliance or efficacy issues.&#xD;
&#xD;
          -  Agreeing to participate in the study and having dated and signed the informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients fulfilling one or more of the following exclusion criteria will not be&#xD;
             included in the study:&#xD;
&#xD;
               -  Inability of patient to use an auto-injector.&#xD;
&#xD;
               -  Treated with biotherapies.&#xD;
&#xD;
               -  Pregnant or breast-feeding patients&#xD;
&#xD;
               -  Male and female patients with reproductive potential who are not willing to use&#xD;
                  effective method of contraception (oral contraceptives, intrauterine device,&#xD;
                  condoms) during study and at least 1 month after the end of the study.&#xD;
&#xD;
               -  Patients with :&#xD;
&#xD;
          -  hypersensitivity to methotrexate or to any of the excipients,&#xD;
&#xD;
          -  severe hepatic impairment,&#xD;
&#xD;
          -  alcohol abuse,&#xD;
&#xD;
          -  severe renal impairment,&#xD;
&#xD;
          -  pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia,&#xD;
             thrombocytopenia or significant anaemia,&#xD;
&#xD;
          -  Immunodeficiency,&#xD;
&#xD;
          -  serious, acute or chronic infections such as tuberculosis and HIV,&#xD;
&#xD;
          -  stomatitis, ulcers of the oral cavity and known active gastrointestinal ulcer disease,&#xD;
&#xD;
          -  concurrent vaccination with live vaccines.&#xD;
&#xD;
               -  Association with probenecid, trimethoprim, phenylbutazone.&#xD;
&#xD;
               -  Any other known medical or surgical history, disorder or disease judged by the&#xD;
                  investigator to be incompatible with the study (such as acute or chronic severe&#xD;
                  organic disease: hepatic, endocrine, neoplasia, haematological, infectious&#xD;
                  diseases, severe psychiatric illness, relevant cardiovascular abnormalities,&#xD;
                  etcâ€¦),&#xD;
&#xD;
               -  Inability of patient to understand the study procedures and thus inability to&#xD;
                  give informed consent.&#xD;
&#xD;
               -  Participation in another clinical study, at the same time as the present study,&#xD;
                  or during the month following the end of the previous study&#xD;
&#xD;
               -  Ward of court.&#xD;
&#xD;
               -  Patient not covered by the Social Security.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SARAUX</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUDRY</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

